Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S. President-elect Donald Trump, who last week refused to rule out military or economic action to take control of Greenland, a semi-autonomous territory of Denmark that is strategically important to Washington.

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations for a possible trade conflict with the United States over Greenland with Denmark's Prime Minister Mette Frederiksen on Thursday.

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss potential measures by the incoming Trump administration amid escalating tensions over Greenland.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.

Novo Nordisk A/S (NYSE:NVO), a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent to finish at $78.69 after following news that the company’s blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027.

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO stock as a strong buy.

including CEO of obesity drugmaker Novo Nordisk, met with the government. Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S. President ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and diabetes treatments. LLY stock has delivered exponential returns from 2018 to mid-2024 of around 1,